EVOLOGIC TECHNOLOGIES GMBH

Their core work

Evologic Technologies is a Vienna-based biotech SME specializing in bioreactor design and industrial scale-up of biological production systems. Their core competence is taking delicate living material — fungal cultures, plant cells, root structures — and turning it into commercially viable large-scale production, including downstream processing. They have built proprietary bioreactor methods for growing arbuscular mycorrhizal fungi (AMF) as agricultural biostimulants, and are extending the same scale-up know-how to plant cell cultures for high-value cosmetic ingredients. In short: they industrialize biology that other people can only culture in small lab batches.

What they specialise in

How they've shifted over time

Their H2020 trajectory shows a clean widening of application domains around one stable core skill: bioreactor scale-up. The first project (2020, coordinator) anchored them firmly in agricultural biotech — mycorrhizal fungi as biostimulants for sustainable food production. By 2021 they had carried the same scale-up and downstream-processing expertise into a very different market — cosmetic actives from plant cells and aeroponic cultivation. The trend is clear: from one biological feedstock (fungi) for one market (agriculture) toward a platform approach where bioreactors serve multiple high-value biological products.

They are turning their fungal scale-up know-how into a broader bioreactor platform for high-value plant-derived compounds, making them a strong partner for anyone needing industrial-scale biological production.

How they like to work

They both lead and follow: they coordinated their own flagship SME project (MycoProScale) and joined a larger research consortium (InnCoCells) as a specialist partner. That pattern suggests a confident small company that drives its core technology but is willing to plug into bigger consortia when their bioreactor expertise fits. With 19 unique partners across 10 countries in just 2 projects, they build broad rather than repeat-pair networks.

They have collaborated with 19 distinct partners across 10 European countries in only two projects, indicating wide consortium exposure per project. No single repeat collaborator dominates the data, suggesting they plug into varied consortia rather than sticking to one cluster.

What sets them apart

Few SMEs can credibly offer industrial-scale bioreactor production for both fungal cultures and plant cells — most specialize in one or the other. Evologic combines a proven coordinator track record (a EUR 2.4M SME-Instrument project of their own) with a participant role in a large cosmetics research action, which means they understand both commercialization and collaborative R&D. For a consortium, this makes them a rare SME that can carry the "industrial scale-up" work package without needing a separate engineering subcontractor.

Highlights from their portfolio

• MycoProScale
  Their coordinator project, worth EUR 2.39M under the SME-2 instrument, built specifically around commercializing a proprietary large-scale mycorrhiza production method.
• InnCoCells
  A major Research & Innovation Action on plant cell–based cosmetics where they apply the same bioreactor scale-up expertise to a completely different market.